Marc Lesnick, PhD

Co-Founder, Chief Development Officer & Board Member
Park Therapeutics, Inc.
Morristown, New Jersey

Presentation(s):

• Poster Number-23 - Cebranopadol, a Novel Potent Analgesic: Binding Affinity to Opioid Receptors and In Vitro Activity

  Poster Abstracts

• Poster Number-22 - Cebranopadol, a Novel Potent Analgesic: Limitations in Physical Dependence Using Short- and Long-term Rodent Studies

  Poster Abstracts